| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| axicabtagene ciloleucel | b-lymphocyte antigen cd19 | biotech | NA | drugbank , DGIDB | B-Cell Lymphomas[MeSHID:D016393] Diffuse Large B-Cell Lymphoma[MeSHID:D016403] Lymphoma Large-Cell Follicular[MeSHID:D008224] High Grade Lymphoma (neoplasm)[MeSHID:D008228] B-Lymphocytes[MeSHID:D001402] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Non-Hodgkin[MeSHID:D008228] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] |
NA | approved | antibody |
| axicabtagene ciloleucel | b-lymphocyte surface antigen b4 | NA | Successful target | TTD , DGIDB | B-Cell Lymphomas[MeSHID:D016393] Diffuse Large B-Cell Lymphoma[MeSHID:D016403] Lymphoma Large-Cell Follicular[MeSHID:D008224] High Grade Lymphoma (neoplasm)[MeSHID:D008228] B-Lymphocytes[MeSHID:D001402] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Non-Hodgkin[MeSHID:D008228] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] |
NA | approved | unknown |
| click here to return to the previous page | ||||||||